Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Exchange: Copenhagen
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Specialty Pharma

Veloxis Pharmaceuticals A/S

+ Add to Watchlist

VELO:DC

0.8000 DKK 0.0050 0.62%

As of 11:06:09 ET on 04/24/2015.

Snapshot for Veloxis Pharmaceuticals A/S (VELO)

Open: 0.8050 Day's Range: 0.7900 - 0.8100 Volume: 579,748
Previous Close: 0.8050 52wk Range: 0.7550 - 2.3000 1-Yr Rtn: -16.67%

Stock Chart for VELO

No chart data available.
  • VELO:DC 0.8000
  • 1D
  • 1M
  • 1Y
0.8050
Interactive VELO Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for VELO

Current P/E Ratio (ttm) -
Estimated P/E(12/2015) -
Relative P/E vs. KFX -
Earnings Per Share (DKK) (ttm) -0.0196
Est. EPS (DKK) (12/2015) -0.1150
Est. PEG Ratio -
Market Cap (M DKK) 1,330.47
Shares Outstanding (M) 1,663.09
30 Day Average Volume 903,415
Price/Book (mrq) 5.2533
Price/Sale (ttm) 10.7782
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 05/20/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for VELO

  • Revenue
  • Net Income (M/DKK)
  • Profit Margin (%)

Company Profile & Key Executives for VELO

Veloxis Pharmaceuticals A/S is a specialty pharmaceutical company. The Company has numerous products in clinical stage and developed products, including a drug for immunosuppression, specifically organ transplantation, and products to combat certain cardiovascular diseases.

William J PolvinoPresident/CEOJohnny StilouExecutive VP/CFO
John D WeinbergExecutive VP/CCO
More Company Profile & Key Executives for VELO

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil